A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder
Launched by DURAMED RESEARCH · May 23, 2008
Trial Information
Current as of June 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women 18 years of age or older, ambulatory, with a history and presentation consistent with urge incontinence ≥ 6 months
- • Able to distinguish between stress and urge incontinence
- • During the Screening Period able to demonstrate the presence of overactive bladder with urge incontinence based on diary entries
- • Others as dictated by FDA-approved protocol
- Exclusion Criteria:
- • Stress incontinence, continuous incontinence or overflow urinary incontinence
- • Chronic illness, neurological dysfunction or injury that could cause incontinence
- • Pregnant, breastfeeding, or gave birth in the last 6 months
- • Others as dictated by FDA-approved protocol
About Duramed Research
Duramed Research is a leading clinical trial sponsor dedicated to advancing medical innovation through rigorous research and development. With a strong focus on enhancing patient outcomes, Duramed specializes in conducting phase I to phase IV clinical trials across a variety of therapeutic areas. The organization is committed to upholding the highest standards of scientific integrity and regulatory compliance, leveraging a team of experienced professionals and state-of-the-art methodologies. By fostering collaborations with healthcare providers and utilizing patient-centric approaches, Duramed Research aims to contribute significantly to the discovery and development of new therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Norfolk, Virginia, United States
Tucson, Arizona, United States
Little Rock, Arkansas, United States
San Diego, California, United States
Colorado Springs, Colorado, United States
Louisville, Kentucky, United States
Port Jefferson, New York, United States
Winston Salem, North Carolina, United States
Oklahoma City, Oklahoma, United States
Jackson, Tennessee, United States
Medford, Oregon, United States
Huntsville, Alabama, United States
New London, Connecticut, United States
Miami, Florida, United States
Tampa, Florida, United States
Boise, Idaho, United States
Lawrenceville, New Jersey, United States
Moorestown, New Jersey, United States
New Brunswick, New Jersey, United States
Pittsburgh, Pennsylvania, United States
Waco, Texas, United States
Seattle, Washington, United States
Tacoma, Washington, United States
Aventura, Florida, United States
Coeur D'alene, Idaho, United States
Jeffersonville, Indiana, United States
Shreveport, Louisiana, United States
Watertown, Massachusetts, United States
Las Vegas, Nevada, United States
Bethany, Oklahoma, United States
Salt Lake City, Utah, United States
Gainesville, Florida, United States
Cleveland, Ohio, United States
Mayfield Heights, Ohio, United States
Columbia, South Carolina, United States
Mobile, Alabama, United States
Denver, Colorado, United States
Fort Wayne, Indiana, United States
Lebanon, New Hampshire, United States
Dallas, Texas, United States
Montgomery, Alabama, United States
Albuquerque, New Mexico, United States
Phoenix, Arizona, United States
Jacksonville, Florida, United States
West Palm Beach, Florida, United States
Augusta, Georgia, United States
Houston, Texas, United States
Williston, Vermont, United States
Savannah, Georgia, United States
Meridian, Idaho, United States
N. Las Vegas, Nevada, United States
New Bern, North Carolina, United States
Eugene, Oregon, United States
Hilton Head Island, South Carolina, United States
Encinitas, California, United States
Los Angeles, California, United States
Danbury, Connecticut, United States
Milford, Connecticut, United States
New Port Richey, Florida, United States
Atlanta, Georgia, United States
Decatur, Georgia, United States
South Bend, Indiana, United States
Newton, Kansas, United States
Wichita, Kansas, United States
Lafayette, Louisiana, United States
Marrero, Louisiana, United States
Philadelphia, Pennsylvania, United States
Pottstown, Pennsylvania, United States
Charlestown, South Carolina, United States
Greensville, South Carolina, United States
San Antonio, Texas, United States
Vancouver, British Columbia, Canada
Oshawa, Ontario, Canada
Thunder Bay, Ontario, Canada
Patients applied
Trial Officials
Duramed Research Protocol Chair
Study Chair
Duramed Research, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials